April 23, 2020 | Joanne Morrison
NIAID/NIH-Sponsored Clinical Trial of Remdesivir on Hospitalized Adult COVID-19-Positive Patients with Pneumonia Will Help Provide Data for Possible FDA Licensure
Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
This research is being conducted through the UMSOM’s Center for Vaccine Development and Global Health’s (CVD), and the Vaccine and Treatment Evaluation Unit (VTEU). It is part a global multicenter National Institutes of Health-sponsored effort to evaluate this experimental treatment for COVID-19 patients with the respiratory disease, first detected in December 2019 in Wuhan, Hubei Province, China. As part of the study, the investigational antiviral drug remdesivir is being administered to patients who test positive for COVID-19 and are hospitalized at the University of Maryland Medical Center (UMMC) with pneumonia.
Karen Kotloff, MD, Professor of Pediatrics, is the Principal Investigator and Justin Ortiz, MD, Associate Professor of Medicine, is Co-Principal Investigator for the clinical trial being conducted in Baltimore. “There are no specific therapeutics approved by the Food and Drug Administration (FDA) with proven effectiveness to treat patients with COVID-19 infection. This trial brings opportunities for our patients at the University of Maryland Medical Center (UMMC) to receive the drug under carefully controlled conditions and provide the critical data needed for licensure of remdesivir as a COVID-19 treatment by the FDA,” said Dr. Kotloff, Associate Director for Clinical Research in CVD.
The clinical trials are taking place over 30 days. Participants in the study are receiving daily intravenous (IV) infusions of remdesivir or a placebo for up to ten days or until they are discharged from UMMC. Those eligible for the trial included adults who are not pregnant and are 18 years or older with laboratory-confirmed COVID-19 as determined by a COVID-19 RT-PCR (polymerase chain reaction) test. Participants must have either radiographic pneumonia, or clinical pneumonia. Individuals with confirmed infection who have mild, cold-like symptoms, or no apparent symptoms, were not included in the study.
“This research into the effectiveness of remdesivir is critical as we face this growing global COVID-19 crisis. Our clinical trial will help us understand how this drug works with essential scientifically based evidence,” said Kathleen Neuzil, MD, MPH, FIDSA the Myron M. Levine MD, DTPH Professor in Vaccinology and Director of UMSOM’s CVD.
As part of the research, researchers collected nasal and/or oral swabs and blood samples four times a day over a ten-day period while the patients were hospitalized, with follow-up testing on days 15 and 29.
At present, there are no specific therapies approved by the FDA to treat people with COVID-19. This infection can cause mild to severe respiratory illness, and symptoms can include fever, cough and shortness of breath. Remdesivir, developed by Gilead Sciences Inc., is an investigational broad-spectrum antiviral treatment. It was previously tested in humans with Ebola virus disease and has shown promise in animal models for treating Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are also caused by other coronaviruses.
“This clinical trial is an important step toward discovering how we can treat this novel coronavirus, which has impacted us globally. With the important collaboration among our infectious disease scientists and other experts around the world, we will hopefully discover therapies and vaccines to protect against this terrible illness,” said Dean E. Albert Reece, MD, PhD, MBA, who is also Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor, University of Maryland School of Medicine.
A Global Effort
Clinical trials of remdesivir are also ongoing at up to 75 sites in the U.S. and internationally. Potential participants in these trials are undergoing a baseline physical exam before receiving treatment. Eligible participants are then randomly assigned either to the investigational treatment group or the placebo group. The study is double-blind, meaning that trial investigators and participants will not know who is receiving remdesivir or a placebo.
Participants in the investigational treatment group will receive 200 milligrams (mg) of remdesivir intravenously on the first day of enrollment to the study. They will receive another 100 mg each day for the duration of hospitalization, for up to 10 days in total. The placebo group will receive, at an equal volume, a solution that resembles remdesivir, but contains inactive ingredients. Researchers will regularly monitor participants and will assign them daily scores based on a predefined scale of clinical outcomes that considers factors such as temperature, blood pressure and use of supplemental oxygen, among others.
This research underway in Baltimore is supported by NIAID. For more than four decades, CVD has operated as part of NIAID’s VTEU network, testing vaccines and therapies for a broad range of infectious diseases including influenza, Ebola and Zika. In 2019, CVD was renewed as one of nine sites in the U.S. that makes up the VTEU network, with funding up to $29 million among the nine sites over the next seven years.
A key role of the CVD VTEU is to quickly respond to public health emergencies like COVID-19 by providing surge capacity and rapid trial implementation. CVD’s role is also to serve as a crucial coordinator of multicenter trials. CVD has assembled an expert and accomplished investigative team with complementary skillsets in all areas necessary to address the NIAID priority areas, including clinical research NS vaccine development. Future research may include Phase I, II, III, and IV clinical trials and studies of new and improved candidate vaccines, therapeutics, and other biologics and drugs provided by or through NIAID.
This Adaptive COVID-19 Treatment Trial (NCT042807050) is a multicenter trial sponsored by the NIAID.
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.
About the Center for Vaccine Development and Global Health
For over 40 years, researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has worked to eliminate vaccine-preventable diseases. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, malaria and other infectious diseases. CVD’s research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. CVD researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact. Currently, these diseases include typhoid, Shigella, E. coli diarrhea, malaria, and other vaccine-preventable infectious diseases. CVD researchers have been involved in critical vaccine development for emerging pathogens such as Ebola and Zika. In addition, CVD’s work focuses on the ever-growing challenge of antimicrobial resistance.
Contact
Joanne Morrison
Director of Marketing and Public Relations
Center for Vaccine Development and Global Health
University of Maryland School of Medicine
jmorrison@som.umaryland.edu
Office: (410) 706-2884
Mobile: (202) 841-3369
Related stories
Tuesday, December 20, 2022
COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds
In the two years since the first COVID-19 vaccines were given to patients in the U.S., the vaccines had the cumulative effect of preventing 18 million hospitalizations and 3 million deaths. That is based on a new modeling analysis conducted by a researcher at the University of Maryland School of Medicine (UMSOM) and her colleagues. Results of the analysis were published by the Commonwealth Fund.
Wednesday, February 16, 2022
Study Shows New Drug Combination More Effective Against SARS-CoV-2
Researchers at the University of Maryland School of Medicine (UMSOM) and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19. The researchers showed that combining the experimental drug brequinar with either of the two drugs already approved by the U.S. Food and Drug Administration for emergency use, remdesivir or molnupiravir, inhibited growth of the SARS-CoV-2 virus in human lung cells and in mice. Their findings suggest that these drugs are more potent when used in combination than individually.
Wednesday, January 26, 2022
Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing
A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).
Thursday, December 16, 2021
Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of Medicine Researchers
An investigational COVID-19 vaccine made by Novavax was found to be 90 percent effective at preventing COVID-19 illness, according to results from a Phase 3 clinical trial published today in the New England Journal of Medicine. The University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health served as one of the trial sites, and Karen Kotloff, MD, Professor of Pediatrics at UMSOM, served as Co-Chair for the trial protocol.
Tuesday, December 14, 2021
UM School of Medicine’s Office of Public Affairs and Communications Honored with 2021 PRSA ‘Best In Maryland’ Award
The University of Maryland School of Medicine (UMSOM)'s Office of Public Affairs & Communications received the Public Relations Society of America (PRSA) 2021 “Best in Maryland Award,” the PRSA’s highest honor, for its COVID-19 Communications program. The award was given at the PRSA Maryland Gala, held on December 9, 2021.
Wednesday, September 08, 2021
UM School of Medicine Reaching Underserved Communities Through Grass Roots Efforts to Increase COVID-19 Vaccination Rates
In an effort to increase COVID-19 vaccination rates among children and families, and ultimately help bring the pandemic under control, the Department of Family & Community Medicine (DFCM) and the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM) are partnering with key community and faith-based groups in Baltimore city to reach the most vulnerable and underserved communities. This partnership will also extend across Maryland, Delaware, Virginia, and West Virginia.
Wednesday, July 07, 2021
UM School of Medicine Researchers Develop Two Rapid Tests for COVID-19 Using Innovative Techniques
Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods.
Wednesday, June 09, 2021
Global Study of Microbes in 60 Cities Finds Each Has Unique Fingerprint of Viruses and Bacteria
Each city has its own unique microbiome, a “fingerprint” of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell.
Tuesday, March 16, 2021
New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel
Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities.
Thursday, January 21, 2021
UM School of Medicine Hosted Media Availability for Ensuring Trust in COVID-19 Vaccine Event
On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and “America’s Doctor,” Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research.
Tuesday, January 05, 2021
Dr. Kathleen Neuzil, World-renowned Leader in Vaccine Research, Receives Moderna Vaccine
Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.
Tuesday, January 05, 2021
University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate
Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD.
Thursday, November 19, 2020
Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine
Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19.
Friday, November 13, 2020
UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses
Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal.
Tuesday, June 16, 2020
UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19
Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government’s Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort.
Tuesday, June 02, 2020
UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa
The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.
Monday, June 01, 2020
In A COVID-19 World, Another Threat to the Health of Our Children
In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations.
Thursday, May 28, 2020
UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique
Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano.
Thursday, May 21, 2020
UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients
Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC.
Tuesday, May 05, 2020
UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19
In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.
Friday, April 10, 2020
University of Maryland School of Medicine Launches New Large Scale COVID-19 Testing Initiative
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland.
Wednesday, April 01, 2020
Important Coronavirus Update from Dean Reece 04-01
I am sure you are aware of Governor Hogan’s Executive Order that requires all residents of Maryland to stay at home, except for essential activities. The Governor continues to emphasize that we are still just at the beginning of this crisis in Maryland. While the State has been taking the lead with early containment efforts, we are now at a critical point. Each of our actions can lessen the expected surge in cases over the next few weeks.
Wednesday, March 25, 2020
Kids & COVID-19 Website Provides Resources for Pediatric Healthcare Providers and Families
The University of Maryland School of Medicine has launched a special COVID-19 website for pediatric healthcare providers and practices, parents, and children. This resource brings together important research, professional guidance for pediatric practices, and practical tips for parents and caregivers.
Wednesday, March 25, 2020
Important Coronavirus Update from Dean Reece
As we continue to move forward in these challenging times, I would like to bring you a message of encouragement and hope. First and foremost, please be assured and confident that we are, and will continue to do, everything we can to ensure the health and well-being of all within our community. As you will see in this briefing, significant steps are being taken by the State of Maryland, the University of Maryland Medical System and the University of Maryland, Baltimore to ensure that everyone is healthy and safe. We must each do whatever is necessary to ensure that our health comes first.
Tuesday, February 25, 2020
Washington Post Visits UM School of Medicine Laboratories, Meets with Scientists About Coronavirus
Result is front-page feature coverage of UMSOM’s leading work in studying the Virus
Wednesday, January 29, 2020
University of Maryland School of Medicine Mobilizes Virus Experts to prepare for Potential Coronavirus Outbreak
As public health officials around the world are monitoring a new coronavirus strain (2019-nCoV) first identified in the Wuhan City, Hubei Province, China, the University of Maryland School of Medicine (UMSOM) is mobilizing its physicians and scientists in the UMSOM’s Center for Vaccine Development and Global Health (CVD), and in its Department of Microbiology & Immunology, to study the virus and test potential vaccines and other therapies. In addition, the UMSOM is collaborating with the University of Maryland Medical Center (UMMC) on rapid response and preparedness planning in the event of a growing outbreak.